Organogenesis offers a portfolio of bioactive and acellular biomaterials products targeting advanced wound care, orthopedics, and spine. The company was originally founded as a spin-off from technology developed at MIT in 1985 and is based in Canton, Massachusetts. It is led by President and CEO Gary S. Gillheeney, Sr. Organogenesis closed a financing facility to support its operations and product work. The company intends to use the funds to continue to enhance its product portfolio. No revenue or user metrics were disclosed in the article. Organogenesis is a Massachusetts-based developer of advanced wound care products and soft tissue regeneration technologies led by President & CEO Gary S. Gillheeney, Sr. Its portfolio includes FDA-approved Apligraf and Dermagraft for bio-active wound healing and the recently launched, FDA-cleared PuraPly Antimicrobial. The company also markets FortaFlex collagen matrix technology for soft tissue reinforcement. Organogenesis plans several additions to the PuraPly wound management line and the launch next year of an FDA-approved Class III PMA burn treatment. It intends to use new funding to expand commercial operations and its sales force and to develop further wound care and surgical products. The article reports the company raised approximately $30M.

Total raised

$50M

Funding rounds

2

Latest round

Debt Financing

Latest activity

May 2017